U.S. Drug and Food Administration U.S. Drug Approval: Growth Hormone Indications: Childhood Growth Hormone Deficiency (GHD), Congenital Ovarian Dysplasia Syndrome (Turner Syndrome), Idiopathic Short Stature (ISS), Small for Gestational Age (SGA), Pre-transplant Chronic Renal Insufficiency, HIV Infection-Related Failure Syndrome, Adult GHD Replacement Therapy, Prader-Willi Syndrome, Short Gut Syndrome, SHOX Gene Deficiency without GHD Willi syndrome, short bowel syndrome, SHOX gene deficiency in children without GHD. Conditions in which recombinant human growth hormone should be contraindicated or used with caution: active tumor, diabetes mellitus with severe complications, Down syndrome, Bloom syndrome, megaloblastic anemia. Bone age is already closed and definitely not suitable for further use in raising lifetime height therapy. It is contraindicated in patients with symptoms of tumor progression and in critically ill patients such as severe systemic infections within acute shock of the organism. The major global pediatric endocrine societies, in 2007, have reached a consensus that growth hormone does not induce tumors, but growth hormone should be used with caution in families with a history of tumors or diabetes. Hepatitis B and C are the high incidence of liver cancer and growth hormone therapy is generally not recommended; Hepatitis B and C in active stage are definitely not treated with growth hormone; Hepatitis B and C in stable stage with normal liver function can be treated with growth hormone. At the time of initial diagnosis, if a girl’s bone age is 14 years old and a boy’s bone age is 15 years old, and the growth rate is less than 2 cm/year, growth hormone therapy is generally not recommended for children with limited growth space.